NCT02132403View on ClinicalTrials.gov

(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Pancreatic Cancer
Interventions
DRUG

BTH1704

BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.

DRUG

IMPRIME PGG

Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.

DRUG

Gemcitabine

Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.

Trial Locations (1)

60612

UI Cancer Center, Chicago

Sponsors

Collaborators (1)

HiberCell, Inc.
All Listed Sponsors
collaborator

HiberCell, Inc.

INDUSTRY

lead

University of Illinois at Chicago

OTHER